Global Immunoglobulin Market Predicted to Surge By 2028
The global immunoglobulin market, essential for treating various immune-related illnesses, was valued at $13.61 billion in 2021 and is projected to grow significantly by 2028.
Sam Morgan
- 2024-01-11
- Updated 09:25 PM ET
(NewsNibs) - According to recent analyses, the global immunoglobulin market is set to experience a compound annual growth rate (CAGR) of 6.77% from 2022 to 2028. This growth is expected to catapult the market's total revenue to $21.49 billion by the endpoint of the forecast period. Immunoglobulins, which are crucial for the treatment of immune-related disorders and play a key role in reducing risks associated with chronic diseases, are becoming increasingly accessible. Available through hospital pharmacies, specialty pharmacies, and other sales channels, these products are widening their reach amidst consumers.
Market Expansion Drivers and Regional Growth
The burgeoning market growth is attributable to several core factors including the introduction of newly developed medications, a rise in the frequency of chronic conditions, and the expansion of pharmacy operations. The Asia-Pacific region, in particular, is poised to be the fastest-growing market for immunoglobulin products. This growth is spurred by an aging population, an uptick in disease prevalence, and intensified research and development efforts within the region.
The immunoglobulin market is stratified into various segments, including type—covering categories such as IgM, IgA, IgD, IgE, and IgG—by delivery mode (Subcutaneous, Intravenous, Intramuscular), application, end-user (Homecare, Hospital & Clinics), and sales channel. Some challenges the market faces are the high costs associated with immunoglobulin therapy and the potential for adverse effects. Nevertheless, the global blood plasma market, significantly tied to the immunoglobulin industry due to its role in treating plasma-related diseases, is also expected to expand at a notable CAGR of 6.13% from 2019 to 2027.
Industry Leaders and Future Prospects
Key players operating in the global immunoglobulin market include prominent companies such as Takeda Pharmaceutical Company Limited and CSL Behring among others. These industry leaders are navigating a landscape where market growth is likely to be influenced by new therapeutic areas and approvals for immunoglobulin therapies. Despite potential headwinds like high treatment expenses and competition from alternative recombinant plasma products, the landscape for immunoglobulins appears to be set for robust growth over the coming years, ensuring continued research, development, and accessibility of these vital therapies worldwide.
